Invention Grant
- Patent Title: Anti-human CD45RC antibodies and uses thereof
-
Application No.: US17277511Application Date: 2019-09-20
-
Publication No.: US12168694B2Publication Date: 2024-12-17
- Inventor: Carole Guillonneau , Ignacio Anegon
- Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
- Applicant Address: FR Paris; FR Nantes; FR Nantes
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE NANTES,CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE NANTES,CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
- Current Assignee Address: FR Paris; FR Nantes; FR Nantes
- Agency: Maier & Maier, PLLC
- Priority: EP18306230 20180921
- International Application: PCT/EP2019/075374 WO 20190920
- International Announcement: WO2020/058495 WO 20200326
- Main IPC: A61P37/06
- IPC: A61P37/06 ; C07K16/28 ; A61K39/00

Abstract:
Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).
Public/Granted literature
- US20220033500A1 ANTI-HUMAN CD45RC ANTIBODIES AND USES THEREOF Public/Granted day:2022-02-03
Information query